| Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma BA Walker, EM Boyle, CP Wardell, A Murison, DB Begum, NB Dahir, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 617 | 2015 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, NM Dahir, PZ Proszek, ... Nature communications 6 (1), 1-11, 2015 | 332 | 2015 |
| APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma BA Walker, CP Wardell, A Murison, EM Boyle, NM Dahir, PZ Proszek, ... Nature communications 6 (1), 1-11, 2015 | 332 | 2015 |
| Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial GH Jackson, FE Davies, C Pawlyn, DA Cairns, A Striha, C Collett, ... The Lancet Oncology 20 (1), 57-73, 2019 | 324 | 2019 |
| Evolutionary biology of high-risk multiple myeloma C Pawlyn, GJ Morgan Nature Reviews Cancer 17 (9), 543-556, 2017 | 235 | 2017 |
| Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients V Shah, AL Sherborne, BA Walker, DC Johnson, EM Boyle, S Ellis, ... Leukemia 32 (1), 102-110, 2018 | 233 | 2018 |
| Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 216 | 2017 |
| Toward personalized treatment in multiple myeloma based on molecular characteristics C Pawlyn, FE Davies Blood 133 (7), 660-675, 2019 | 182 | 2019 |
| Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? C Pawlyn, L Fowkes, S Otero, JR Jones, KD Boyd, FE Davies, GJ Morgan, ... Leukemia 30 (6), 1446-1448, 2016 | 152 | 2016 |
| Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma S Bird, A Panopoulou, RL Shea, M Tsui, R Saso, A Sud, S West, K Smith, ... The Lancet Haematology, 2021 | 140 | 2021 |
| Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells A Tumber, A Nuzzi, ES Hookway, SB Hatch, S Velupillai, C Johansson, ... Cell chemical biology 24 (3), 371-380, 2017 | 119 | 2017 |
| Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells A Tumber, A Nuzzi, ES Hookway, SB Hatch, S Velupillai, C Johansson, ... Cell chemical biology 24 (3), 371-380, 2017 | 119 | 2017 |
| Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ... Blood cancer journal 7 (3), e549-e549, 2017 | 113 | 2017 |
| Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network H Ludwig, M Boccadoro, P Moreau, J San-Miguel, M Cavo, C Pawlyn, ... Leukemia, 1-14, 2020 | 106 | 2020 |
| The spectrum and clinical impact of epigenetic modifier mutations in myeloma C Pawlyn, MF Kaiser, C Heuck, L Melchor, CP Wardell, A Murison, ... Clinical Cancer Research 22 (23), 5783-5794, 2016 | 102 | 2016 |
| Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations C Pawlyn, L Melchor, A Murison, CP Wardell, A Brioli, EM Boyle, ... Blood 125 (5), 831-840, 2015 | 98 | 2015 |
| Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial JR Jones, DA Cairns, WM Gregory, C Collett, C Pawlyn, R Sigsworth, ... Blood cancer journal 6 (12), e506-e506, 2016 | 91 | 2016 |
| A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and … G Cook, KL Royle, C Pawlyn, A Hockaday, V Shah, MF Kaiser, SR Brown, ... The Lancet Haematology 6 (3), e154-e166, 2019 | 89 | 2019 |
| Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated … JR Jones, N Weinhold, C Ashby, BA Walker, C Wardell, C Pawlyn, ... Haematologica 104 (7), 1440, 2019 | 83 | 2019 |
| Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis F Gay, G Jackson, L Rosiñol, SA Holstein, P Moreau, S Spada, F Davies, ... JAMA oncology 4 (10), 1389-1397, 2018 | 79 | 2018 |
